Major antibody-drug conjugates (ADC) have secured positive clinical results in treating breast cancer. ADCs under development by global pharmaceutical companies have shown to be effective in various types of breast cancer, including triple-negative breast cancer, hormone-positive (HR+)/HER2-negative breast cancer. With these results, latecomers have established a foundation to secure indications for breast cancer, following the cases of Kadcyla, Enhertu, and Trodelvy.

According to industry sources on June 4th, clinical achievements of several ADCs, including Padcev, datopotamab deruxtecan, and sacituzumab tirumotecan, were presented at the American Society of Clinical Oncology (ASCO 2024) annual meetin